{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:36:18Z","timestamp":1777869378040,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00108-025-02021-0","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T14:44:50Z","timestamp":1764686690000},"page":"588-594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Myelofibrose\u00a0\u2013 abwarten oder behandeln?","Myelofibrosis: watch and wait or treat?"],"prefix":"10.1007","volume":"67","author":[{"given":"Martin","family":"Griesshammer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"issue":"5","key":"2021_CR1","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41375-025-02569-8","volume":"39","author":"F Perner","year":"2025","unstructured":"Perner\u00a0F, Pahl\u00a0HL, Zeiser\u00a0R, Heidel\u00a0FH (2025) Malignant JAK-signaling: at the interface of inflammation and malignant transformation. Leukemia 39(5):1011\u20131030. https:\/\/doi.org\/10.1038\/s41375-025-02569-8","journal-title":"Leukemia"},{"key":"2021_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.26050","volume":"96","author":"A Tefferi","year":"2021","unstructured":"Tefferi\u00a0A (2021) Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 96:145\u2013162. https:\/\/doi.org\/10.1002\/ajh.26050","journal-title":"Am J Hematol"},{"issue":"14","key":"2021_CR3","doi-asserted-by":"publisher","first-page":"1382872","DOI":"10.3389\/fonc.2024.1382872","volume":"24","author":"M Breccia","year":"2024","unstructured":"Breccia\u00a0M, Palandri\u00a0F, Polverelli\u00a0N et\u00a0al (2024) Epidemiology and disease characteristics of myelofibrosis: a\u00a0comparative analysis between Italy and global perspectives. Front Oncol 24(14):1382872. https:\/\/doi.org\/10.3389\/fonc.2024.1382872","journal-title":"Front Oncol"},{"issue":"11","key":"2021_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber\u00a0DA, Orazi\u00a0A, Hasserjian\u00a0RP et\u00a0al (2022) International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228. https:\/\/doi.org\/10.1182\/blood.2022015850","journal-title":"Blood"},{"issue":"7","key":"2021_CR5","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury\u00a0JD, Solary\u00a0E, Abla\u00a0O et\u00a0al (2022) The 5th\u00a0edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36(7):1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"2021_CR6","volume-title":"Leitlinie \u201ePrim\u00e4re Myelofibrose (PMF)\u201c \u2013 Stand 09\/2025","year":"2025","unstructured":"Grie\u00dfhammer\u00a0M (Hrsg) (2025) Leitlinie \u201ePrim\u00e4re Myelofibrose (PMF)\u201c \u2013 Stand 09\/2025. DGHO, Berlin (https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/primaere-myelofibrose-pmf)"},{"key":"2021_CR7","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi\u00a0A, Guglielmelli\u00a0P, Lasho\u00a0TL et\u00a0al (2018) MIPSS70+ version\u00a02.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J\u00a0Clin Oncol 36:1769\u20131770. https:\/\/doi.org\/10.1200\/JCO.2018.78.9867","journal-title":"J Clin Oncol"},{"issue":"1","key":"2021_CR8","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","volume":"11","author":"N Kr\u00f6ger","year":"2024","unstructured":"Kr\u00f6ger\u00a0N, Bacigalupo\u00a0A, Barbui\u00a0T et\u00a0al (2024) Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group. Lancet Haematol 11(1):e62\u2013e74. https:\/\/doi.org\/10.1016\/S2352-3026(23)00305-8","journal-title":"Lancet Haematol"},{"issue":"5","key":"2021_CR9","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/ajh.27252","volume":"99","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann\u00a0N, Hobbs\u00a0GS, Campodonico\u00a0E et\u00a0al (2024) Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: a\u00a0global collaborative analysis. Am J Hematol 99(5):844\u2013853. https:\/\/doi.org\/10.1002\/ajh.27252","journal-title":"Am J Hematol"},{"issue":"2","key":"2021_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa2408941","volume":"392","author":"N Gagelmann","year":"2025","unstructured":"Gagelmann\u00a0N, Quarder\u00a0M, Badbaran\u00a0A, Rathje\u00a0K, Janson\u00a0D, L\u00fcck\u00a0C, Richter\u00a0J, Marquard\u00a0F, Oechsler\u00a0S, Massoud\u00a0R, Klyuchnikov\u00a0E, Rudolph\u00a0I, Sch\u00e4fersk\u00fcpper\u00a0M, Niederwieser\u00a0C, Heidenreich\u00a0S, Berger\u00a0C, Fehse\u00a0B, Wolschke\u00a0C, Ayuk\u00a0F, Kr\u00f6ger\u00a0N (2025) Clearance of driver mutations after transplantation for myelofibrosis. N\u00a0Engl J Med 392(2):150\u2013160. https:\/\/doi.org\/10.1056\/NEJMoa2408941","journal-title":"N Engl J Med"},{"key":"2021_CR11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek\u00a0S, Mesa\u00a0RA, Gotlib\u00a0J et\u00a0al (2012) A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N\u00a0Engl J Med 366:799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"key":"2021_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison\u00a0C, Kiladjian\u00a0JJ, Al-Ali\u00a0HK et\u00a0al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N\u00a0Engl J Med 366:787\u2013798. https:\/\/doi.org\/10.1056\/NEJMoa1110556","journal-title":"N Engl J Med"},{"key":"2021_CR13","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","volume":"4","author":"A Mullally","year":"2020","unstructured":"Mullally\u00a0A, Hood\u00a0J, Harrison\u00a0C, Mesa\u00a0R (2020) Fedratinib in myelofibrosis. Blood Adv 4:1792\u20131800. https:\/\/doi.org\/10.1182\/bloodadvances.2019000954","journal-title":"Blood Adv"},{"issue":"34","key":"2021_CR14","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa\u00a0RA, Kiladjian\u00a0J, Catalano\u00a0JV et\u00a0al (2017) A\u00a0Phase\u00a0III randomized trial of momelotinib versus ruxolitinib in Janus Kinase Inhibitor-naive patients with myelofibrosis. J\u00a0Clin Oncol 35(34):3844\u20133850. https:\/\/doi.org\/10.1200\/JCO.2017.73.4418","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021_CR15","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","volume":"5","author":"CN Harrison","year":"2018","unstructured":"Harrison\u00a0CN, Vannucchi\u00a0AM, Platzbecker\u00a0U et\u00a0al (2018) Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY-2): a\u00a0randomized, open-label, phase\u00a03\u00a0trial. Lancet Hematol 5(2):e73\u2013e81. https:\/\/doi.org\/10.1016\/S2352-3026(17)30237-5","journal-title":"Lancet Hematol"},{"issue":"10373","key":"2021_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","volume":"401","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek\u00a0S, Gerds\u00a0AT, Vannucchi\u00a0AM et\u00a0al (2023) MOMENTUM Study Investigators. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase\u00a03\u00a0study. Lancet 401(10373):269\u2013280. https:\/\/doi.org\/10.1016\/S0140-6736(22)02036-0","journal-title":"Lancet"},{"issue":"1","key":"2021_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00277-025-06191-7","volume":"104","author":"M Griesshammer","year":"2025","unstructured":"Griesshammer\u00a0M, Al-Ali\u00a0HK, Eckardt\u00a0JN et\u00a0al (2025) How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF)\u2014practical approaches of a\u00a0German expert panel discussion in 2024. Ann Hematol 104(1):295\u2013306. https:\/\/doi.org\/10.1007\/s00277-025-06191-7","journal-title":"Ann Hematol"},{"issue":"5","key":"2021_CR18","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3390\/cells10051034","volume":"10","author":"D Tremblay","year":"2021","unstructured":"Tremblay\u00a0D, Mascarenhas\u00a0J (2021) Next generation therapeutics for the treatment of myelofibrosis. Cells 10(5):1034. https:\/\/doi.org\/10.3390\/cells10051034","journal-title":"Cells"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-02021-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-025-02021-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-02021-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:38:04Z","timestamp":1777556284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-025-02021-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2021"],"URL":"https:\/\/doi.org\/10.1007\/s00108-025-02021-0","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Griesshammer gibt Honorare f\u00fcr Advisory Boards sowie f\u00fcr Beratungen und Vortr\u00e4ge von folgenden Firmen an: AOP Orphan, Novartis, BMS, AbbVie, Pfizer, Roche, AstraZeneca, Lilly und GSK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}